ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and ...

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

Eli Lilly & Company LLY and Pfizer PFE are both large-cap U.S. pharmaceutical giants with diversified drug portfolios and ...

Eli Lilly’s investigational obesity pill helped lower weight and blood sugar in patients with obesity and type 2 diabetes.

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

The Asia–Pacific region has a high global burden of cardiovascular disease.1 The region, home to more than 60% of the world's population, spans the vast and diverse geographies from Oceania through ...

The drug, based on Nobel Prize-winning gene-editing technology CRISPR-Cas9, reaches the liver cells and splices out the ...